| Abstract: | One hundred and seventeen patients (75 per cent women) with established osteoporosis were entered into a clinical trial assessing two regimes of cyclical etidronate and calcium (Cacit). Some subjective parameters of clinical outcome were assessed prior to, and during, treatment. Patient acceptability of therapy was also examined. There was a significant reduction in pain score (median scores from a 10-point visual analogue scale at 0, 6–12 and 15–24 months were 4, 2 and 1, respectively) and in analgesic consumption (32 per cent, 51 per cent and 65 per cent of patients at 0, 6–12 and 15–24 months, respectively, were using no analgesics). Sleeping patterns improved significantly during the study but there was no change in hypnotic consumption. Sixty-four per cent of patients felt there had been an improvement in their condition and 79 per cent felt that attending the clinic had helped them come to terms with osteoporosis. Etidronate was well tolerated: 23 per cent of patients experienced mild gastrointestinal side effects; 94 per cent were prepared to continue with treatment indefinitely. However, 43 per cent felt their daily routine was interrupted by taking etidronate. The Cacit was poorly tolerated: 50 per cent of patients experienced gastrointestinal side effects, 28 per cent had to discontinue calcium because of side effects and 24 per cent felt their daily routine was altered by taking calcium. Eighty-five per cent were, however, prepared to continue with some form of calcium supplement indefinitely. In conclusion, etidronate therapy was an acceptable form of treatment in this group of patients and provided some symptomatic improvement. However, the choice of calcium supplement was less acceptable and may lead to non-compliance with treatment. |
